• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Richter Syndrome

Richter Syndrome - 14 Studies Found

Completed : Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
: Leukemia
: 2007-03-23
:
  • Drug: Cytarabine 1 g/m^2 given

Completed : Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL or Richter's Transformation
: Chronic Lymphocytic Leukemia
: 2015-08-24
:
  • Drug: Pembrolizumab IV immunot

Completed : Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
:
  • B-cell Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Drug: PCI-32765 420 mg PO dail

Active, not recruiting : ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
:
  • Non-hodgkin Lymphoma
  • Multiple Myeloma
  • Hodgkin Lymphoma : 2015-02-07
    :
    • Drug: Acalabrutinib oral

<<< Previous
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.